Literature DB >> 16831051

Update on pancreatic endocrine tumors.

Wendy L Frankel1.   

Abstract

Endocrine tumors of the pancreas represent 1% to 2% of all pancreatic neoplasms. The tumors tend to have an indolent behavior, and long-term survival is common. There is no gender or age predilection. Patients can present with symptoms due to hormonal excess or a local mass effect or be asymptomatic. The tumors tend to be solid and well circumscribed. Typical microscopic findings include an organoid pattern of growth, with cells containing scant to moderate amounts of cytoplasm, and nuclei with dispersed chromatin and inconspicuous nucleoli. The morphologic spectrum of these tumors can be variable, and the differential diagnosis includes chronic pancreatitis with neuroendocrine hyperplasia, ductal adenocarcinoma, solid pseudopapillary tumor, acinar cell carcinoma, and pancreatoblastoma. The classification of these tumors remains controversial, and prognosis is difficult to predict, but important features include metastasis and invasion of adjacent structures. Resection remains the mainstay of surgical treatment. It is important to be aware that unusual morphologic variants of pancreatic endocrine tumors are common, and immunohistochemical stains can help avoid misdiagnosis.

Entities:  

Mesh:

Year:  2006        PMID: 16831051     DOI: 10.5858/2006-130-963-UOPET

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  10 in total

Review 1.  Diagnostic evaluation of solid pancreatic masses.

Authors:  Jeffrey L Tokar; Rohit Walia
Journal:  Curr Gastroenterol Rep       Date:  2013-10

2.  EUS-FNA for pancreatic neuroendocrine tumors: a tertiary cancer center experience.

Authors:  Muslim Atiq; Manoop S Bhutani; Mehmet Bektas; Jeffrey E Lee; Yun Gong; Eric P Tamm; Chintan P Shah; William A Ross; James Yao; Gottumukkala S Raju; Xuemei Wang; Jeffrey H Lee
Journal:  Dig Dis Sci       Date:  2011-10-01       Impact factor: 3.199

3.  Nonfunctioning pancreatic endocrine tumor with extension into the main pancreatic duct: report of a case.

Authors:  Naoki Yazawa; Toshihide Imaizumi; Ken-ichi Okada; Masahiro Matsuyama; Shoichi Dowaki; Kosuke Tobita; Yasuo Ohtani; Kyoji Ogoshi; Kenichi Hirabayashi; Hiroyasu Makuuchi
Journal:  Surg Today       Date:  2011-05-01       Impact factor: 2.549

4.  The impact of preoperative endoscopic ultrasound on the surgical management of pancreatic neuroendocrine tumours.

Authors:  Fahad Alsohaibani; David Bigam; Norman Kneteman; A M James Shapiro; Gurpal Singh Sandha
Journal:  Can J Gastroenterol       Date:  2008-10       Impact factor: 3.522

Review 5.  Von Hippel-Lindau Disease.

Authors:  Jennifer J Findeis-Hosey; Kelly Q McMahon; Sarah K Findeis
Journal:  J Pediatr Genet       Date:  2016-04-04

6.  Molecular pathology of pancreatic neuroendocrine tumors.

Authors:  Mingyi Chen; Michael Van Ness; Yangtong Guo; Jeffrey Gregg
Journal:  J Gastrointest Oncol       Date:  2012-09

7.  Performance of endoscopic ultrasound-guided fine needle aspiration in diagnosing pancreatic neuroendocrine tumors.

Authors:  Jane Bernstein; Berrin Ustun; Ahmed Alomari; Fang Bao; Harry R Aslanian; Uzma Siddiqui; David Chhieng; Guoping Cai
Journal:  Cytojournal       Date:  2013-05-29       Impact factor: 2.091

8.  Diagnostic yield of endoscopic ultrasound in patients with hypoglicemia and insulinoma suspected.

Authors:  Félix Ignacio Téllez-Ávila; Gladys Yolanda Acosta-Villavicencio; Carlos Chan; Jorge Hernández-Calleros; Luis Uscanga; Francisco Valdovinos-Andraca; Miguel Ángel Ramírez-Luna
Journal:  Endosc Ultrasound       Date:  2015 Jan-Mar       Impact factor: 5.628

9.  Differential diagnosis between pancreatic neuroendocrine and solid pseudopapillary neoplasms on endoscopic ultrasound-guided fine-needle aspiration. An immunohistochemical study.

Authors:  Emad M Raddaoui; Majid A Almadi; Abdulrahman M Aljebreen; Faisal A Alsaif; Ahlam A AlShedoukhy; Abed H Al-Lehibi; Khalid A Almohameed; Apostolos V Tsolakis; Mousa A AlAbbadi; Amna R Almutrafi
Journal:  Saudi Med J       Date:  2016-07       Impact factor: 1.484

10.  Significance of chromogranin A and synaptophysin in pancreatic neuroendocrine tumors.

Authors:  Tatsuo Tomita
Journal:  Bosn J Basic Med Sci       Date:  2020-08-03       Impact factor: 3.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.